Benitec Biopharma INC. (BNTC) — SEC Filings

Overview

Benitec Biopharma INC. (BNTC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 2, 2025: Benitec Biopharma Inc. filed an 8-K on December 2, 2025, reporting on matters submitted to a vote of security holders as of December 1, 2025. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at 3940 Trust Way, H

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bearish, 48 neutral. The dominant filing sentiment for Benitec Biopharma INC. is neutral.

Filing Type Overview

Benitec Biopharma INC. (BNTC) has filed 24 8-K, 4 10-Q, 2 DEFA14A, 3 DEF 14A, 1 10-K, 1 8-K/A, 9 SC 13G/A, 2 SC 13D/A, 1 S-1, 2 SC 13G, 1 SC 13D with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• Benitec Biopharma Files 8-K on Shareholder Votes — 8-K · Dec 2, 2025 Risk: low
  Benitec Biopharma Inc. filed an 8-K on December 2, 2025, reporting on matters submitted to a vote of security holders as of December 1, 2025. The filing details
• Benitec's Q1 Loss Widens 77% on Soaring G&A Costs — 10-Q · Nov 14, 2025 Risk: high
  Benitec Biopharma Inc. reported a significant increase in net loss for the three months ended September 30, 2025, reaching $8.965 million, up from $5.059 millio
• Benitec Biopharma Files Proxy Supplement — DEFA14A · Nov 12, 2025 Risk: low
  Benitec Biopharma Inc. filed a supplemental proxy statement on November 12, 2025, for its annual meeting of stockholders scheduled for December 1, 2025. This fi
• 8-K Filing — 8-K · Nov 7, 2025
• Benitec Biopharma Reports Director/Officer Changes & More — 8-K · Nov 3, 2025 Risk: medium
  Benitec Biopharma Inc. filed an 8-K on November 3, 2025, reporting events as of November 2, 2025. The filing indicates changes related to directors and officers
• Benitec Biopharma Sets Virtual 2025 Annual Meeting, Key Votes Ahead — DEF 14A · Oct 14, 2025 Risk: medium
  Benitec Biopharma Inc. (BNTC) is holding its 2025 Annual Meeting of Stockholders virtually on December 1, 2025, at 1:00 p.m. Pacific Time. Key proposals include
• Benitec Biopharma Restates Financials, Cites Material Weakness — 10-K · Sep 22, 2025 Risk: high
  Benitec Biopharma Inc. (BNTC) filed its 10-K for the fiscal year ended June 30, 2025, revealing a restatement of prior period financial statements due to unreco
• Benitec Biopharma Restates Financials — 8-K · Sep 12, 2025 Risk: high
  Benitec Biopharma Inc. announced on September 10, 2025, that it will not rely on previously issued financial statements or related audit reports. This decision
• Benitec Biopharma Files 8-K Report — 8-K · Jul 9, 2025 Risk: low
  On July 9, 2025, Benitec Biopharma Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and a Regulation FD disclosure. No
• Benitec Biopharma Files Q3 10-Q Report — 10-Q · May 14, 2025 Risk: medium
  Benitec Biopharma Inc. filed its Q3 10-Q report for the period ending March 31, 2025. The filing details financial information and operational updates for the c
• Benitec Biopharma Files 8-K — 8-K · Mar 28, 2025 Risk: medium
  On March 26, 2025, Benitec Biopharma Inc. filed an 8-K report. The filing indicates an 'Other Event' without specifying further details in the provided text. Th
• Benitec Biopharma Enters Material Definitive Agreement — 8-K · Mar 27, 2025 Risk: medium
  On March 26, 2025, Benitec Biopharma Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offic
• Benitec Biopharma Files 8-K: Material Agreement & Financials — 8-K · Mar 26, 2025 Risk: medium
  On March 25, 2025, Benitec Biopharma Inc. entered into a material definitive agreement. The company also reported on other events and filed financial statements
• Benitec Biopharma Files 8-K for Other Events — 8-K · Mar 20, 2025 Risk: medium
  On March 20, 2025, Benitec Biopharma Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." Specific det
• Benitec Biopharma Files 8-K — 8-K · Mar 19, 2025 Risk: low
  On March 19, 2025, Benitec Biopharma Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No
• Benitec Biopharma Files 10-Q for Period Ending Dec 31, 2024 — 10-Q · Feb 14, 2025 Risk: medium
  Benitec Biopharma Inc. filed its 10-Q for the period ending December 31, 2024. The filing details financial performance and operational updates for the company.
• Benitec Biopharma Files 8-K/A Amendment on Director/Officer Changes — 8-K/A · Dec 31, 2024 Risk: medium
  Benitec Biopharma Inc. filed an amendment (8-K/A) on December 31, 2024, to a previous report concerning the departure of directors or certain officers, election
• Benitec Biopharma Reports Director Changes and Officer Compensation Updates — 8-K · Dec 13, 2024 Risk: medium
  On December 9, 2024, Benitec Biopharma Inc. reported a change in its board of directors and executive compensation arrangements. The filing indicates a departur
• Benitec Biopharma Files 8-K on Security Holder Rights — 8-K · Dec 10, 2024 Risk: medium
  On December 9, 2024, Benitec Biopharma Inc. filed an 8-K report detailing material modifications to security holder rights and amendments to its articles of inc
• SC 13G/A Filing — SC 13G/A · Dec 6, 2024
• Benitec Biopharma Reports on Shareholder Vote — 8-K · Dec 6, 2024 Risk: low
  Benitec Biopharma Inc. filed an 8-K on December 6, 2024, reporting on a matter submitted to a vote of its security holders on December 4, 2024. The filing detai
• Suvretta Capital Management Files 13D/A for Benitec Biopharma — SC 13D/A · Nov 18, 2024 Risk: medium
  On November 18, 2024, Suvretta Capital Management, LLC filed an amendment (Amendment #2) to its Schedule 13D for Benitec Biopharma Inc. The filing indicates a c
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Benitec Biopharma Files Proxy Materials — DEFA14A · Nov 14, 2024 Risk: low
  Benitec Biopharma Inc. filed a Definitive Additional Materials filing (DEFA14A) on November 14, 2024. This filing is related to proxy materials and does not inv
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• SC 13G/A Filing — SC 13G/A · Nov 6, 2024
• SC 13G/A Filing — SC 13G/A · Oct 25, 2024
• Benitec Biopharma Files 2024 Proxy Statement — DEF 14A · Oct 22, 2024 Risk: low
  Benitec Biopharma Inc. filed its definitive proxy statement (DEF 14A) on October 23, 2024, for its 2024 Annual Meeting of Stockholders scheduled for December 4,
• Benitec Biopharma Files Current Report — 8-K · Oct 15, 2024 Risk: low
  Benitec Biopharma Inc. filed an 8-K on October 15, 2024, reporting an event on October 12, 2024. The filing is a current report pursuant to Section 13 or 15(d)
• Benitec Biopharma Files 8-K: Material Agreement & Financials — 8-K · Oct 11, 2024 Risk: medium
  On October 11, 2024, Benitec Biopharma Inc. filed an 8-K report. The filing indicates the company entered into a Material Definitive Agreement and also includes
• Benitec Biopharma Files 8-K with Financials — 8-K · Oct 8, 2024 Risk: low
  On October 8, 2024, Benitec Biopharma Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or
• Suvretta Capital Amends Benitec Biopharma Stake — SC 13D/A · Sep 30, 2024 Risk: medium
  Suvretta Capital Management, LLC, through Averill Madison Master Fund, Ltd. and Averill Master Fund, Ltd., has amended its Schedule 13D filing regarding Benitec
• Benitec Biopharma Files 8-K for Operations Update — 8-K · Sep 26, 2024 Risk: low
  Benitec Biopharma Inc. filed an 8-K on September 26, 2024, to report on its results of operations and financial condition, as well as to file financial statemen
• Benitec Biopharma Reports Director Changes and Shareholder Votes — 8-K · Sep 5, 2024 Risk: medium
  Benitec Biopharma Inc. filed an 8-K on August 29, 2024, reporting on the departure of directors, election of new directors, and compensatory arrangements. The f
• Benitec Biopharma Schedules August 29th Stockholder Meeting — DEF 14A · Jul 29, 2024 Risk: low
  Benitec Biopharma Inc. is holding a Special Meeting of Stockholders on August 29, 2024, to vote on important matters. The company is filing its Definitive Proxy
• Benitec Biopharma Files 8-K Report — 8-K · Jul 15, 2024 Risk: low
  On July 15, 2024, Benitec Biopharma Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the filing of Financial Statements and
• Benitec Biopharma Announces Director Changes and Officer Compensation Updates — 8-K · Jul 1, 2024 Risk: medium
  On June 26, 2024, Benitec Biopharma Inc. filed an 8-K report detailing the departure of Director Dr. David J. Wood and the appointment of Dr. Christopher P. De
• Benitec Biopharma Files S-1 Registration Statement — S-1 · May 16, 2024 Risk: low
  Benitec Biopharma Inc. (BNTC) filed a IPO Registration (S-1) with the SEC on May 16, 2024. Benitec Biopharma Inc. filed an S-1 registration statement with the S
• Benitec Biopharma Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: medium
  Benitec Biopharma Inc. (BNTC) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Benitec Biopharma Inc. filed a 10-Q report for the period ending Mar
• SC 13G Filing — SC 13G · Apr 29, 2024
• SC 13G Filing — SC 13G · Apr 29, 2024
• Suvretta Capital Discloses Stake in Benitec Biopharma — SC 13D · Apr 29, 2024 Risk: medium
  On April 29, 2024, Suvretta Capital Management, LLC, along with Averill Madison Master Fund, Ltd. and Averill Master Fund, Ltd., filed a Schedule 13D regarding
• Benitec Biopharma Files 8-K: Material Agreement & Equity Sales — 8-K · Apr 19, 2024 Risk: medium
  On April 17, 2024, Benitec Biopharma Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company
• Benitec Biopharma Files 8-K Report — 8-K · Apr 18, 2024 Risk: low
  On April 18, 2024, Benitec Biopharma Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and includes a Regulation FD Dis
• SC 13G/A Filing — SC 13G/A · Apr 11, 2024
• Benitec Biopharma Appoints New CMO, Adds Directors — 8-K · Mar 8, 2024 Risk: medium
  Benitec Biopharma Inc. announced on March 6, 2024, the appointment of Dr. Joseph S. Carillo as Chief Medical Officer and the election of Ms. Jennifer L. D. Alli
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Benitec Biopharma Files 8-K for Financial Results — 8-K · Feb 13, 2024 Risk: medium
  Benitec Biopharma Inc. filed an 8-K on February 13, 2024, to report its results of operations and financial condition. The filing also includes financial statem
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024

Risk Profile

Risk Assessment: Of BNTC's 38 recent filings, 3 were flagged as high-risk, 21 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Benitec Biopharma INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $0
• Net Income: -$8.965M
• EPS: -$0.22
• Debt-to-Equity: 0.03
• Cash Position: $94.479M
• Operating Margin: -100.0%
• Total Assets: $96.027M
• Total Debt: $2.428M

Key Executives

• Dr. Jerel Banks
• Andrew Nathanson
• Dr. David J. Wood
• Dr. Christopher P. De Souza
• Dr. Joseph S. Carillo
• Ms. Jennifer L. D. Allison
• Mr. David S. Wood
• Dr. B.K. Singh

Industry Context

Benitec Biopharma operates in the highly competitive and rapidly evolving biotechnology sector, specifically focusing on genetic medicines. This field is characterized by significant R&D investment, long development cycles, and high regulatory hurdles. Companies in this space often rely on novel platforms like RNAi and gene therapy to address unmet medical needs, but face substantial risks related to clinical trial success and market adoption.

Top Tags

corporate-governance (8) · filing (5) · financials (5) · 8-K (4) · regulatory-filing (4) · shareholder-vote (3) · Biotechnology (3) · management-change (3) · 10-Q (3) · material-agreement (3)

Key Numbers

• SEC File Number: 001-39267 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 84-4620206 — Company's tax identification number.
• Net Loss: $8.965M — Increased 77.2% from $5.059M in Q1 2024
• General & Administrative Expenses: $6.433M — Increased 191.6% from $2.206M in Q1 2024
• Revenue: $0 — No revenue generated in Q1 2025 or Q1 2024
• Cash and Cash Equivalents: $94.479M — Decreased from $97.744M at June 30, 2025
• Share-based Compensation Expense: $5.180M — Significantly increased from $435K in Q1 2024
• Accumulated Deficit: $237.141M — Increased from $228.176M at June 30, 2025
• Net Loss Per Share (Basic & Diluted): $0.22 — Increased from $0.18 in Q1 2024
• Weighted Average Shares Outstanding: 41,521,280 — Increased from 27,883,624 in Q1 2024
• Shares of common stock outstanding: 26,250,469 — As of the record date, October 10, 2025
• Unexercised pre-funded warrants: 15,270,806 — Potential shares to be issued, excluding from current outstanding shares
• Number of Class III directors: 2 — To be elected at the 2025 Annual Meeting
• Annual Meeting start time: 1:00 p.m. — Pacific Time on December 1, 2025
• Days prior to annual meeting: 90 — Minimum notice for stockholder proposals under bylaws

Frequently Asked Questions